Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis.
OBJECTIVE: To examine the clinical outcomes and costs associated with Staphylococcus aureus bacteremia among hemodialysis-dependent patients. DESIGN: Prospectively identified cohort study. SETTING: A tertiary-care university medical center in North Carolina. PATIENTS: Two hundred ten hemodialysis-d...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2005
|
| _version_ | 1797105217092714496 |
|---|---|
| author | Engemann, J Friedman, J Reed, S Griffiths, R Szczech, L Kaye, K Stryjewski, M Reller, L Schulman, K Corey, G Fowler, V |
| author_facet | Engemann, J Friedman, J Reed, S Griffiths, R Szczech, L Kaye, K Stryjewski, M Reller, L Schulman, K Corey, G Fowler, V |
| author_sort | Engemann, J |
| collection | OXFORD |
| description | OBJECTIVE: To examine the clinical outcomes and costs associated with Staphylococcus aureus bacteremia among hemodialysis-dependent patients. DESIGN: Prospectively identified cohort study. SETTING: A tertiary-care university medical center in North Carolina. PATIENTS: Two hundred ten hemodialysis-dependent adults with end-stage renal disease hospitalized with S. aureus bacteremia. RESULTS: The majority of the patients (117; 55.7%) underwent dialysis via tunneled catheters, and 29.5% (62) underwent dialysis via synthetic arteriovenous fistulas. Vascular access was the suspected source of bacteremia in 185 patients (88.1%). Complications occurred in 31.0% (65), and the overall 12-week mortality rate was 19.0% (40). The mean cost of treating S. aureus bacteremia, including readmissions and outpatient costs, was $24,034 per episode. The mean initial hospitalization cost was significantly greater for patients with complicated versus uncomplicated S. aureus bacteremia ($32,462 vs $17,011; P = .002). CONCLUSION: Interventions to decrease the rate of S. aureus bacteremia are needed in this high-risk, hemodialysis-dependent population. |
| first_indexed | 2024-03-07T06:44:20Z |
| format | Journal article |
| id | oxford-uuid:fa5c89cd-0e12-4608-87b3-36e705c9f780 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:44:20Z |
| publishDate | 2005 |
| record_format | dspace |
| spelling | oxford-uuid:fa5c89cd-0e12-4608-87b3-36e705c9f7802022-03-27T13:05:08ZClinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:fa5c89cd-0e12-4608-87b3-36e705c9f780EnglishSymplectic Elements at Oxford2005Engemann, JFriedman, JReed, SGriffiths, RSzczech, LKaye, KStryjewski, MReller, LSchulman, KCorey, GFowler, V OBJECTIVE: To examine the clinical outcomes and costs associated with Staphylococcus aureus bacteremia among hemodialysis-dependent patients. DESIGN: Prospectively identified cohort study. SETTING: A tertiary-care university medical center in North Carolina. PATIENTS: Two hundred ten hemodialysis-dependent adults with end-stage renal disease hospitalized with S. aureus bacteremia. RESULTS: The majority of the patients (117; 55.7%) underwent dialysis via tunneled catheters, and 29.5% (62) underwent dialysis via synthetic arteriovenous fistulas. Vascular access was the suspected source of bacteremia in 185 patients (88.1%). Complications occurred in 31.0% (65), and the overall 12-week mortality rate was 19.0% (40). The mean cost of treating S. aureus bacteremia, including readmissions and outpatient costs, was $24,034 per episode. The mean initial hospitalization cost was significantly greater for patients with complicated versus uncomplicated S. aureus bacteremia ($32,462 vs $17,011; P = .002). CONCLUSION: Interventions to decrease the rate of S. aureus bacteremia are needed in this high-risk, hemodialysis-dependent population. |
| spellingShingle | Engemann, J Friedman, J Reed, S Griffiths, R Szczech, L Kaye, K Stryjewski, M Reller, L Schulman, K Corey, G Fowler, V Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. |
| title | Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. |
| title_full | Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. |
| title_fullStr | Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. |
| title_full_unstemmed | Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. |
| title_short | Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. |
| title_sort | clinical outcomes and costs due to staphylococcus aureus bacteremia among patients receiving long term hemodialysis |
| work_keys_str_mv | AT engemannj clinicaloutcomesandcostsduetostaphylococcusaureusbacteremiaamongpatientsreceivinglongtermhemodialysis AT friedmanj clinicaloutcomesandcostsduetostaphylococcusaureusbacteremiaamongpatientsreceivinglongtermhemodialysis AT reeds clinicaloutcomesandcostsduetostaphylococcusaureusbacteremiaamongpatientsreceivinglongtermhemodialysis AT griffithsr clinicaloutcomesandcostsduetostaphylococcusaureusbacteremiaamongpatientsreceivinglongtermhemodialysis AT szczechl clinicaloutcomesandcostsduetostaphylococcusaureusbacteremiaamongpatientsreceivinglongtermhemodialysis AT kayek clinicaloutcomesandcostsduetostaphylococcusaureusbacteremiaamongpatientsreceivinglongtermhemodialysis AT stryjewskim clinicaloutcomesandcostsduetostaphylococcusaureusbacteremiaamongpatientsreceivinglongtermhemodialysis AT rellerl clinicaloutcomesandcostsduetostaphylococcusaureusbacteremiaamongpatientsreceivinglongtermhemodialysis AT schulmank clinicaloutcomesandcostsduetostaphylococcusaureusbacteremiaamongpatientsreceivinglongtermhemodialysis AT coreyg clinicaloutcomesandcostsduetostaphylococcusaureusbacteremiaamongpatientsreceivinglongtermhemodialysis AT fowlerv clinicaloutcomesandcostsduetostaphylococcusaureusbacteremiaamongpatientsreceivinglongtermhemodialysis |